The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | Overcoming resistance to IO with sitravatinib + tocilizumab in patients with lung cancer
Qing Zhou, MD, PhD, of the Guangdong Lung Cancer Institute, Guangzhou, China, discusses the results of a Phase I clinical trial investigating the combination of sitravatinib with tocilizumab in order to overcome resistance to checkpoint blockade therapies. Promising findings from this study have resulted in a randomized Phase III trial currently underway. This interview took place during the European Society for Medical Oncology (ESMO) 2021 congress.
